The MS Wire - A Column by Ed Tobias

Florida, MS biomarker, Lemtrada, nasal spray

Diagnosed with MS at age 32 in 1980, Ed has written the “MS Wire” column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.

MS news notes: Biomarkers, cow’s milk, EBV vaccine

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Is it MS or something else? Should all autoimmune diseases that damage myelin be called MS? Probably not, according…

Who says MS doesn’t hurt?

Multiple sclerosis (MS) is a pain in my butt — and other places, too. It hasn’t always been that way. For many years post-diagnosis, I didn’t notice much pain. But of the 43 years I’ve lived with MS, it’s hurt for the past 15. Usually, it’s just…

MS news notes: DMT survey, keto diet, Gilenya generic

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Neurologists comment on DMTs available for RRMS There are 20 disease-modifying therapies (DMTs) available to treat MS in the…

MS news notes: AI and MS diagnosis, gut bacteria, DMTs

Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Could MS be predicted by an artificial intelligence tool? Wouldn’t it be great if there was a way to predict…

Why pills became the most popular first DMTs for MS

Note: This column describes the author’s own experiences with several disease-modifying therapies for multiple sclerosis. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. Times, they’ve been a-changing for disease-modifying therapies (DMTs). When I was diagnosed with multiple…

MS news notes: Stem cell therapy, genetic variant, diet

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Another study shows positive results with stem cell therapy Yet another study has concluded that autologous hematopoietic…

MS news notes: Clemastine, MS retrospective, PIPE-791

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Myelin repair and clemastine The Multiple Sclerosis News Today story “MRI method detects myelin repair with…

Air4All hopes to make flying with a wheelchair easier

I’ve done quite a bit of flying, for business and pleasure, over the 42 years I’ve lived with multiple sclerosis (MS). It’s not easy traveling by air with my scooter, and I can’t imagine trying to fly with a 450-pound power wheelchair. Actually, I don’t have to imagine.

MS news notes: Foralumab, Ocrevus, Kesimpta, exercise

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Foralumab shows early positive results for SPMS I’ll say up front that this is a very small study.

MS news notes: Frexalimab, vidofludimus calcium, Briumvi

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Is CD40L a better way to control MS inflammation? CD40L is a protein that’s involved with activation of…

Let’s talk facts about MS and COVID-19 vaccines

Since the early days of the COVID-19 vaccination program, disinformation claiming that the vaccines can induce multiple sclerosis (MS) has swirled around social media. Recently, there’s been a resurgence of this type of post, sparked by a report published on the World Health Organization (WHO) website titled “…

MS News Notes: EBV, nabiximols, MRT-6160

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A closer look at the EBV-MS link Much has been written over the past few years about the…

Want to take your MS to the beach?

Memorial Day, the unofficial start of summer vacation in the U.S., is fast approaching. It’s almost time for some summer beach fun — if we can get there. Beaches can be difficult, if not impossible, to access for many people with multiple sclerosis (MS). But times seem to be…

My 5 wishes for the future of multiple sclerosis

A recent post on the MS-Selfie blog asks and answers this question: What is the “greatest unmet need” concerning multiple sclerosis (MS)? Professor Gavin Giovannoni, the London-based neurologist who writes that blog, lists five unmet needs, many of which I agree with. But those needs are from the viewpoint…